Serum Cortistatin Level in Type 2 Diabetes Mellitus and Its Relationship with Nonalcoholic Fatty Liver Disease

References

• Aliyeva IJ. Variability of the type II diabetes mellitus incidence rate of population of cities in the Republic of Azerbaijan. J Chem Health Risks. 2021;11:233–239.
   Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, et al. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Bhala N, Younes R, Bugianesi E. Epidemiology and natural history of patients with NAFLD. Curr Pharm Des. 2013;19(29):5169–5176. doi:10.2174/13816128113199990336
   PubMed Web of Science ®Google Scholar
• Tretyakova VA, Zhernakova NI, Arisheva OS, et al. Meta-analysis of non-alcoholic fatty liver disease and electromechanical reconstruction of myocardium. Arch Razi Inst. 2022;77(1):123–128. doi:10.22092/ARI.2021.356678.1891
   PubMedGoogle Scholar
• Li FP, Zhang SQ, Wang F, et al. Insulin resistance and islet beta cell function in type 2 diabetes mellitus and non alcoholic fatty liver disease. Zhonghua Nei Ke Za Zhi. 2009;48(11):940–943.
   PubMedGoogle Scholar
• Spier AD, de Lecea L. Cortistatin: a member of the somatostatin neuropeptide family with distinct physiological functions. Brain Res Brain Res Rev. 2000;33(2–3):228–241. doi:10.1016/S0165-0173(00)00031-X
   PubMedGoogle Scholar
• Dalm VA, Van Hagen PM, de Krijger RR, et al. Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues. Clin Endocrinol (Oxf). 2004;60(5):625–629. doi:10.1111/j.1365-2265.2004.02024.x
   PubMed Web of Science ®Google Scholar
• Broglio F, Arvat E, Benso A, et al. Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans. J Clin Endocrinol Metab. 2002;87(8):3783–3790. doi:10.1210/jcem.87.8.8749
   PubMed Web of Science ®Google Scholar
• Grottoli S, Gasco V, Broglio F, et al. Cortistatin-17 and somatostatin-14rvatplay the same effects on growth hormone, prolactin, and insulin secretion in patients with acromegaly or prolactinoma. J Clin Endocrinol Metab. 2006;91(4):1595–1599. doi:10.1210/jc.2005-1837
   PubMed Web of Science ®Google Scholar
• Córdoba-Chacón J, Gahete MD, Pozo-Salas AI, et al. Cortistatin is not a somatostatin analogue but stimulates prolactin release and inhibits GH and ACTH in a gender-dependent fashion: potential role of ghrelin. Endocrinology. 2011;152(12):4800–4812. doi:10.1210/en.2011-1542
   PubMed Web of Science ®Google Scholar
• Chen W, Fu Y, Yin X, et al. Circulating levels of cortistatin are correlated with metabolic parameters in patients with newly diagnosed type 2 diabetes mellitus. Peptides. 2017;94:86–90. doi:10.1016/j.peptides.2017.05.008
   PubMed Web of Science ®Google Scholar
• Benitez R, Caro M, Andres-Leon E, et al. Cortistatin regulates fibrosis and myofibroblast activation in experimental hepatotoxic- and cholestatic-induced liver injury. Br J Pharmacol. 2022;179(10):2275–2296. doi:10.1111/bph.15752
   PubMed Web of Science ®Google Scholar
• Xidakis C, Mastrodimou N, Notas G, et al. RT-PCR and immunocytochemistry studies support the presence of somatostatin, cortistatin and somatostatin receptor subtypes in rat Kupffer cells. Regul Pept. 2007;143(1–3):76–82. doi:10.1016/j.regpep.2007.03.005
   PubMedGoogle Scholar
• National Workshop on Fatty Liver and Alcoholic Liver Disease, Chinese Society of Hepatology, Chinese Medical Association. Guidelines of prevention and treatment for nonalcoholic fatty liver disease: a 2018 update. Zhonghua Gan Zang Bing Za Zhi. 2018;26(3):195–203. doi:10.3760/cma.j.issn.1007-3418.2018.03.008
   PubMedGoogle Scholar
• Li Y, Wang J, Tang Y, et al. Bidirectional association between nonalcoholic fatty liver disease and type 2 diabetes in Chinese population: evidence from the Dongfeng-Tongji cohort study. PLoS One. 2017;12(3):e0174291. doi:10.1371/journal.pone.0174291
   PubMed Web of Science ®Google Scholar
• Katsuki A, Sumida Y, Gabazza EC, et al. Homeostasis model assessment is a reliable indicator of insulin resistance during follow-up of patients with type 2 diabetes. Diabetes Care. 2001;24(2):362–365. doi:10.2337/diacare.24.2.362
   PubMed Web of Science ®Google Scholar
• Bermu´dez V, Cano R, Cano C, et al. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. Am J Ther. 2008;15(4):409–416. doi:10.1097/MJT.0b013e318160b909
   PubMed Web of Science ®Google Scholar
• Akbas M, Koltan SO, Koyuncu FM, et al. Decreased maternal serum cortistatin levels in pregnancies with gestational diabetes mellitus. J Matern Fetal Neonatal Med. 2020;33(7):1239–1244. doi:10.1080/14767058.2019.1627321
   PubMed Web of Science ®Google Scholar
• Soriano S, Castellano-Muñoz M, Rafacho A, et al. Cortistatin regulates glucose-induced electrical activity and insulin secretion in mouse pancreatic beta-cells. Mol Cell Endocrinol. 2019;479:123–132. doi:10.1016/j.mce.2018.09.009
   PubMed Web of Science ®Google Scholar
• Papotti M, Tarabra E, Allia E, et al. Presence of cortistatin in the human pancreas. J Endocrinol Invest. 2003;26(8):RC15–8. doi:10.1007/BF03347348
   PubMed Web of Science ®Google Scholar
• Giordano R, Picu A, Bonelli L, et al. The activation of somatostatinergic receptors by either somatostatin-14 or cortistatin-17 often inhibits ACTH hypersecretion in patients with Cushing’s disease. Eur J Endocrinol. 2007;157(4):393–398. doi:10.1530/EJE-07-0147
   PubMed Web of Science ®Google Scholar
• Benso A, Gottero C, Prodam F, et al. Effects of cortistatin-14 and somatostatin-14 on the endocrine response to hexarelin in humans. J Endocrinol Invest. 2003;26(7):599–603. doi:10.1007/BF03347014
   PubMed Web of Science ®Google Scholar
• Oseini AM, Sanyal AJ. Therapies in non-alcoholic steatohepatitis (NASH). Liver Int. 2017;37(Suppl1):97–103. doi:10.1111/liv.13302
   PubMedGoogle Scholar
• Gruber HE, Hoelscher GL, Bethea SF, et al. Cortistatin is endogenous to the human intervertebral disc and exerts in vitro mitogenic effects on annulus cells and a downregulatory effect on TNF-α expression. Spine J. 2014;14(12):2995–3001. doi:10.1016/j.spinee.2014.06.002
   PubMed Web of Science ®Google Scholar
• Li D, He HL, Yao MZ, et al. Cortistatin is dysregulated in skin tissue of patients with psoriasis vulgaris and suppresses keratinocyte proliferation in vitro. Int J Dermatol. 2015;54(8):e309–314. doi:10.1111/ijd.12836
   PubMed Web of Science ®Google Scholar
• Henning RJ. Type-2 diabetes mellitus and cardiovascular disease. Future Cardiol. 2018;14(6):491–509. doi:10.2217/fca-2018-0045
   PubMed Web of Science ®Google Scholar
• Tian QP, Feng XR, Pang YZ, et al. Relationship between plasma cortistatin and coronary heart disease. Beijing Da Xue Xue Bao Yi Xue Ban. 2009;41(5):537–540.
   PubMedGoogle Scholar
• Liu Y, Yin XH, Qi YF. Progress in biological effects of cortistatin. Sheng Li Ke Xue Jin Zhan. 2009;40(3):219–224.
   PubMedGoogle Scholar
• Chanclon B, Martinez-Fuentes AJ, Gracia-Navarro F. Role of SST, CORT and ghrelin and its receptors at the endocrine pancreas. Front Endocrinol. 2012;3:114.
   PubMedGoogle Scholar